To summarize, adopting a lipidomics approach, an investigation was performed that aimed at analyzing the elements that contribute to the divergent response of patients with advanced NSCLC harboring negative driver mutations when subjected to a combined therapeutic regimen of anlotinib and PD-1/PD-L1 inhibitors. The gene discussed is CD274; the disease is non-small cell lung carcinoma.